Journal of Clinical Oncology, Vol 26, No 12 (April 20), 2008: pp. 1993-1999
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.12.3588
Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Nancy U. Lin,
Lisa A. Carey,
Minetta C. Liu,
Jerry Younger,
Steven E. Come,
Matthew Ewend,
Gordon J. Harris,
Elizabeth Bullitt,
Annick D. Van den Abbeele,
John W. Henson,
Xiaochun Li,
Rebecca Gelman,
Harold J. Burstein,
Elizabeth Kasparian,
David G. Kirsch,
Ann Crawford,
Fred Hochberg,
Eric P. Winer
From the Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center, Boston, MA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; and the Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
Corresponding author: Eric P. Winer, MD, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: ewiner{at}partners.org
Purpose One third of women with advanced human epidermal growth factor receptor 2 (HER-2)–positive breast cancer develop brain metastases; a subset progress in the CNS despite standard approaches. Medical therapies for refractory brain metastases are neither well-studied nor established. We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2–positive brain metastases.
Patients and Methods Patients had HER-2–positive breast cancer, progressive brain metastases, prior trastuzumab treatment, and at least one measurable metastatic brain lesion. Patients received lapatinib 750 mg orally twice a day. Tumor response was assessed by magnetic resonance imaging every 8 weeks. The primary end point was objective response (complete response [CR] plus partial response [PR]) in the CNS by Response Evaluation Criteria in Solid Tumors (RECIST). Secondary end points included objective response in non-CNS sites, time to progression, overall survival, and toxicity.
Results Thirty-nine patients were enrolled. All patients had developed brain metastases while receiving trastuzumab; 37 had progressed after prior radiation. One patient achieved a PR in the brain by RECIST (objective response rate 2.6%, 95% conditional CI, 0.21% to 26%). Seven patients (18%) were progression free in both CNS and non-CNS sites at 16 weeks. Exploratory analyses identified additional patients with some degree of volumetric reduction in brain tumor burden. The most common adverse events (AEs) were diarrhea (grade 3, 21%) and fatigue (grade 3, 15%).
Conclusion The study did not meet the predefined criteria for antitumor activity in highly refractory patients with HER-2–positive brain metastases. Because of the volumetric changes observed in our exploratory analysis, further studies are underway utilizing volumetric changes as a primary end point.
Supported by an AVON Partners for Progress Award CA89393-AV-55P, National Cancer Institute Specialized Program in Research Excellence in Breast Cancer at Dana-Farber Cancer Institute/Harvard Cancer Center (DF/HCC; Grant No. CA89393) and the University of North Carolina (Grant No. CA58223); American Society of Clinical Oncology Young Investigator Award (N.U.L.); Breast Cancer Research Foundation (E.P.W. and N.U.L.); Leaf Fund (D.G.K.); National Institutes of Health (NIH) Grant No. R01EB000219-NIBIB (E.B.); Tumor Imaging Metrics Core (G.J.H and A.V.D.A.) under DF/HCC National Cancer Institute Comprehensive Cancer Cenger Grant No. P30 CA006516; and NIH Grant No. M01RR00046 (L.A.C).
Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006.
Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Johnston, J. Pippen Jr, X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, et al.
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
J. Clin. Oncol.,
November 20, 2009;
27(33):
5538 - 5546.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Leyland-Jones
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases
J. Clin. Oncol.,
November 1, 2009;
27(31):
5278 - 5286.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al.
Third consensus on medical treatment of metastatic breast cancer
Ann. Onc.,
November 1, 2009;
20(11):
1771 - 1785.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Niwinska, M. Murawska, and K. Pogoda
Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT)
Ann. Onc.,
October 19, 2009;
(2009)
mdp407v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Pienkowski and C. C. Zielinski
Trastuzumab treatment in patients with breast cancer and metastatic CNS disease
Ann. Onc.,
August 28, 2009;
(2009)
mdp353v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Maher, J. Mietz, C. L. Arteaga, R. A. DePinho, and S. Mohla
Brain Metastasis: Opportunities in Basic and Translational Research
Cancer Res.,
August 1, 2009;
69(15):
6015 - 6020.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist,
April 1, 2009;
14(4):
320 - 368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. U. Lin, V. Dieras, D. Paul, D. Lossignol, C. Christodoulou, H.-J. Stemmler, H. Roche, M. C. Liu, R. Greil, E. Ciruelos, et al.
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Clin. Cancer Res.,
February 15, 2009;
15(4):
1452 - 1459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Polli, K. L. Olson, J. P. Chism, L. St. John-Williams, R. L. Yeager, S. M. Woodard, V. Otto, S. Castellino, and V. E. Demby
An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)
Drug Metab. Dispos.,
February 1, 2009;
37(2):
439 - 442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Belkacemi and A. Kuten
Are Volumetric Changes of Brain Metastases the Best Evaluation of Efficacy?
J. Clin. Oncol.,
November 1, 2008;
26(31):
5137 - 5138.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Paul, J. A. Trovato, and J. Thompson
Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer
Am. J. Health Syst. Pharm.,
September 15, 2008;
65(18):
1703 - 1710.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Lapatinib for Treatment of Metastatic Brain Metastases
Journal Watch Oncology and Hematology,
May 13, 2008;
2008(513):
2 - 2.
[Full Text]
|
 |
|
|